Huons Co. Ltd Asset Resilience Ratio
Huons Co. Ltd asset resilience ratio. Huons Co. Ltd (243070) has an Asset Resilience Ratio of 1.98% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Huons Co. Ltd (243070) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Huons Co. Ltd (2016–2024)
Asset resilience ratio of Huons Co. Ltd from 2016 to 2024. This chart shows how Huons Co. Ltd's Asset Resilience Ratio has changed over time. Read 243070 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Huons Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Huons Co. Ltd (243070) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩12.76 Billion | 1.98% |
| Total Liquid Assets | ₩12.76 Billion | 1.98% |
Asset Resilience Insights
- Limited Liquidity: Huons Co. Ltd maintains only 1.98% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Huons Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Huons Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Huons Co. Ltd Asset Resilience Ratio by Year (2016–2024)
Huons Co. Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Huons Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.36% | ₩68.87 Billion ≈ $46.68 Million |
₩606.29 Billion ≈ $410.87 Million |
-3.59pp |
| 2023-12-31 | 14.95% | ₩80.33 Billion ≈ $54.44 Million |
₩537.29 Billion ≈ $364.11 Million |
-2.95pp |
| 2022-12-31 | 17.90% | ₩84.62 Billion ≈ $57.35 Million |
₩472.63 Billion ≈ $320.29 Million |
+1.85pp |
| 2021-12-31 | 16.05% | ₩70.13 Billion ≈ $47.52 Million |
₩436.90 Billion ≈ $296.08 Million |
-12.71pp |
| 2020-12-31 | 28.76% | ₩119.78 Billion ≈ $81.18 Million |
₩416.50 Billion ≈ $282.26 Million |
+11.95pp |
| 2019-12-31 | 16.81% | ₩50.49 Billion ≈ $34.21 Million |
₩300.34 Billion ≈ $203.54 Million |
+1.95pp |
| 2018-12-31 | 14.86% | ₩37.35 Billion ≈ $25.31 Million |
₩251.37 Billion ≈ $170.35 Million |
-7.05pp |
| 2017-12-31 | 21.91% | ₩47.33 Billion ≈ $32.07 Million |
₩216.00 Billion ≈ $146.38 Million |
+9.38pp |
| 2016-12-31 | 12.53% | ₩22.47 Billion ≈ $15.23 Million |
₩179.34 Billion ≈ $121.54 Million |
-- |
About Huons Co. Ltd
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other ch… Read more